Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 3
2009 6
2010 3
2011 3
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Clinical significance of ABCB1 genotyping in oncology.
Hamidovic A, Hahn K, Kolesar J. Hamidovic A, et al. J Oncol Pharm Pract. 2010 Mar;16(1):39-44. doi: 10.1177/1078155209104380. Epub 2009 Apr 28. J Oncol Pharm Pract. 2010. PMID: 19401306 Free PMC article.
Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study.
Attia S, Traynor AM, Kim K, Merchant JJ, Hoang T, Ahuja HG, Beatty PA, Hansen RM, Masters GA, Oettel KR, Shapiro GR, Larson MM, Larson ML, Schiller JH. Attia S, et al. J Thorac Oncol. 2008 Sep;3(9):1018-25. doi: 10.1097/JTO.0b013e3181834fa1. J Thorac Oncol. 2008. PMID: 18758305 Free PMC article. Clinical Trial.
A phase I study of an oral simulated FOLFOX with high dose capecitabine.
Mulkerin D, LoConte NK, Holen KD, Thomas JP, Alberti D, Marnocha R, Kolesar J, Eickhoff J, Oliver K, Feierabend C, Wilding G. Mulkerin D, et al. Invest New Drugs. 2009 Oct;27(5):461-8. doi: 10.1007/s10637-008-9210-8. Epub 2009 Jan 8. Invest New Drugs. 2009. PMID: 19129971 Free PMC article. Clinical Trial.
Cytotoxic Evaluation of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, 3-AP, in Peripheral Blood Lymphocytes of Patients with Refractory Solid Tumors using Electron Paramagnetic Resonance.
Kolesar JM, Sachidanandam K, Schelman WR, Eickhoff J, Holen KD, Traynor AM, Alberti DB, Thomas JP, Chitambar CR, Wilding G, Antholine WE. Kolesar JM, et al. Exp Ther Med. 2011 Jan;2(1):119-123. doi: 10.3892/etm.2010.165. Exp Ther Med. 2011. PMID: 21373381 Free PMC article.
The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors.
Choi BS, Alberti DB, Schelman WR, Kolesar JM, Thomas JP, Marnocha R, Eickhoff JC, Ivy SP, Wilding G, Holen KD. Choi BS, et al. Cancer Chemother Pharmacol. 2010 Oct;66(5):973-80. doi: 10.1007/s00280-010-1250-z. Epub 2010 Feb 2. Cancer Chemother Pharmacol. 2010. PMID: 20127092 Free PMC article. Clinical Trial.